Go Pro
→ $40,000,000,000,000 (From American Alternative) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
-5.1%		$0.01
$0.00
▼
$0.02
$981K-1.3215,814 shs100,678 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$2.71
-1.5%		$13.35
$2.35
▼
$1,280.95
$930K-0.0759,275 shs231,773 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.00
$0.02
$0.00
▼
$0.33
$274K0.736,059 shsN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%-3.90%0.00%-12.94%-47.52%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.00%-42.46%-79.32%-91.97%-99.72%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%0.00%-58.82%-96.50%-98.42%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
-5.1%		$0.01
$0.00
▼
$0.02
$981K-1.3215,814 shs100,678 shs
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$2.71
-1.5%		$13.35
$2.35
▼
$1,280.95
$930K-0.0759,275 shs231,773 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.00
$0.02
$0.00
▼
$0.33
$274K0.736,059 shsN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
▼
$6.56
$1.04M1.36315,915 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%-3.90%0.00%-12.94%-47.52%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.00%-42.46%-79.32%-91.97%-99.72%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%0.00%-58.82%-96.50%-98.42%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%0.00%0.00%+150.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
1.00
SellN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NKGN, NMTR, EVFM, and JAGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.09N/AN/A($2.64) per share0.00
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
$11.51M0.08N/AN/A($1,590.93) per share0.00
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.13N/AN/AN/A-46.42%-91.97%-61.93%N/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$53.43M-$248.88N/AN/AN/A-187.88%N/A-131.45%11/12/2026 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$1.68N/AN/AN/AN/AN/A-479.36%N/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A

Latest NKGN, NMTR, EVFM, and JAGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026Q2 2026
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
-$782.25-$235.50+$546.75-$15.70$4.24 million$1.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.35
0.69
0.40
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59

Institutional Ownership

CompanyInstitutional Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
12.04%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%

Insider Ownership

CompanyInsider Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.01%
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
0.18%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120132.53 million113.12 millionNot Optionable
Jaguar Animal Health, Inc. stock logo
JAGX
Jaguar Animal Health
47340,000344,000No Data
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A130.60 million40.29 millionNot Optionable
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data

Recent News About These Companies

What is a prepayment meter?
August 24, 2024  |  uswitch.comU
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
July 28, 2024  |  pharmaphorum.comP
Energy firms likely to miss smart meter deadline, warns Which?
December 14, 2023  |  bbc.comB
Deal reached to sell some assets of bankrupt Raleigh firm
November 8, 2023  |  bizjournals.comhttps://www.bizjournals.com/triangle/news/2023/11/08/9meters-bankruptcy-asset-sale-raleigh-pharma.html
9 Meters Biopharma, Inc. (NMTRQ)
November 7, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/quote/NMTRQ/history/
TRACK AND FIELD/ Yamagata sets Japan record in 100-meter sprint with 9.95 seconds
October 28, 2023  |  asahi.comA
9 Meters Biopharma Inc (NMTRQ)
October 17, 2023  |  investing.comhttps://www.investing.com/equities/monster-digital-inc-historical-data
Vintage Meters Reborn As Steam Punk Clock
October 10, 2023  |  hackaday.comH
9 Meters Biopharma (OTC: NMTR.Q)
August 16, 2023  |  fool.comhttps://www.fool.com/quote/otc/nmtr.q/
Insider Sale Alert: 9 Meters Biopharma Inc. [NMTR] – Is it Time to sell?
July 25, 2023  |  knoxdaily.comK
9 Meters Biopharma Inc. [NASDAQ: NMTR] Sees Decrease in Stock Value
July 21, 2023  |  knoxdaily.comK
Raleigh firm joins worrying trend of bankruptcies for drugmakers
July 18, 2023  |  bizjournals.comhttps://www.bizjournals.com/triangle/news/2023/07/18/9-meters-biopharma-files-for-bankruptcy.html
Drug developer 9 Meters Biopharma files for bankruptcy protection
July 18, 2023  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/drug-developer-9-meters-biopharma-files-bankruptcy-protection-2023-07-18/
Why Are 9 Meters Biopharma Shares Nosediving Today?
July 18, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/why-9-meters-biopharma-shares-153623871.html
Examining the Potential Price Growth of 9 Meters Biopharma Inc. (NMTR)
July 18, 2023  |  knoxdaily.comK
Temperato resigns as CEO of Raleigh drugmaker
May 30, 2023  |  bizjournals.comhttps://www.bizjournals.com/triangle/news/2023/05/30/9-meters-biopharma-ceo-temperato-resigns.html
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
May 30, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/9-meters-biopharma-announces-management-132500126.html?.tsrc=rss
9 Meters Biopharma (NASDAQ: NMTR)
May 27, 2023  |  fool.comhttps://www.fool.com/quote/nasdaq/nmtr/
NMTR - 9 Meters Biopharma, Inc.
May 25, 2023  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/quote/NMTR/history/
Citigroup Maintains 9 Meters Biopharma (NMTR) Neutral Recommendation
May 19, 2023  |  msn.comhttps://www.msn.com/en-us/money/companies/citigroup-maintains-9-meters-biopharma-nmtr-neutral-recommendation/ar-AA1boI8a

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.0074 0.00 (-5.13%)
As of 09/18/2026 03:50 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Jaguar Animal Health stock logo

Jaguar Animal Health NASDAQ:JAGX

$2.71 -0.04 (-1.45%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$2.71 0.00 (0.00%)
As of 09/18/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.0021 0.00 (0.00%)
As of 09/18/2026

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas